Physician-initiated trial investigating the Efficacy of the self-expandable iVOLUTION nitinol stent for treatment of femoropopliteal lesions.
DESCRIPTION
Device
iVolution
Number of patients
120
Follow up
2-years
Type of lesions
Femoropopliteal arteries TASC A & B
OUTCOMES
1 year1
Primary patency
2 years2
Primary patency
Freedom from TLR
1- Bosiers at al. The Journal of Cardiovascular Surgery 2019 August;60(4):490-5
2- Presented by M. Bosiers at LINC 2019
CONCLUSIONS
“iVolution stent is a very effective treatment for femoropopliteal TASC A&B lesions.”
Final results show that the iVolution stent is a valid and effective alternative to treat femoropopliteal TASC A&B lesions. The outstanding flexibility and the high-quality nitinol of the stent makes the difference.
MAIN INVESTIGATOR
Dr. Marc Bosiers
São Paulo, Brazil
